Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine

This study has 3 arms with 5 patients enrolled in each of the three arms. The three treatment arms are based upon whether the patient has previously received Abraxane-Gemcitabine or FOLFIRINOX or single-agent Gemcitabine without radiographic evidence of disease progression for a minimum of 8 weeks , based on the investigator's opinion, but with a rising Carbohydrate antigen 19-9 (CA 19-9) levels. Rising CA 19-9 is defined as an increased over baseline of > 20% in two consecutive time points within 8 days of each other. Study sites will provide all chemotherapy for patients participating in the study as a "standard of care". DSF/Cu (Disulfiram + Copper Gluconate) will be provided by the Sponsor and shipped from the Sponsor's central depot to the study sites. Sufficient amounts of DSF/Cu will be available at the study site prior to enrolling patients in the study.

• Safety Laboratories (Diagnostic test): Complete blood cell count (CBC) w Differential, comprehensive metabolic panel (CMP), Prothrombin time/international normalized ratio (PT/INR) Activated Partial Thromboplastin Time (aPTT), Urinalysis
• AE Assessment (Other): Assessment of Adverse Events (AE)
• Physical Exam (Other): Physical Exam, Weight, Vital Signs, Eastern Cooperative Oncology Group (ECOG) Performance Status
• Concomitant Medication Review (Other): Prior and Concomitant Medication Review
• Tumor Imaging (Diagnostic test): Tumor CT or MRI
• nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate (Drug): nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
• FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate (Drug): FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing
• Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate (Drug): Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing

Primary outcomes

• CA19-9 Plasma Level [From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months]: Change in plasma CA19-9 level (at least 30%) from baseline

Secondary outcomes

• Complete Tumor Response [From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months]: Complete response rate as defined by CT scan using RECIST 1.1 criteria
• Partial Response [From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months]: Partial response as defined by CT scan using RECIST 1.1 criteria
• Stable Disease [From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months]: Complete response as defined by CT scan using RECIST 1.1 criteria
• Overall Response Rate [From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months]: Overall response rate as defined by CT scan using RECIST 1.1 criteria
• Overall Survival [From date of enrollment until date of death assessed up to 100 months]: The length of time from the start of treatment that patients are still alive
• Serum Albumin [From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months]: Change in serum albumin level as a result of treatment
• Body Weight [From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months]: Change in body weight as a result of treatment
• Muscle Area at the L3 Level - Optional [From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months]: Change in muscle area at the L3 level using CT scan. Only is L3 is visualized with normally scheduled standard of care CT Scan
• Incidence of Toxicities [From date of enrollment until the date of follow-up, 30 days after last treatment]: Physical exam and laboratory testing will be completed and toxicity grading assessed and documented using CTCAE version 4.0

Other outcomes

• Disulfiram/Copper Gluconate Serum Levels - Area Under the Curve (AUC) [Day 0 (pre-Cycle 1 Day 1) at pre-dose, 2 hours, 4 hours, 24 hours and 4 hours post-dose Cycle 1 Day 7]: Optional Day 0 (pre-Cycle 1 Day 1) at pre-dose, 2 hours, 4 hours, 24 hours and 4 hours post-dose Cycle 1 Day 7

Sex: All, ages: 18 Years to 105 Years

Inclusion Criteria:

1. Patients must have histologically confirmed adenocarcinoma of the pancreas that is metastatic and for which potential curative measures, such as resection of an isolated metastasis, are not available. Patients with islet cell neoplasms are excluded.
2. Patient should currently be receiving a chemotherapy regimen comprising FOLFIRINOX or Abraxane-Gemcitabine or single-agent Gemcitabine as front-line treatment for metastatic disease. Patients who have had chemotherapy in the adjuvant or neoadjuvant setting are eligible.
3. Patients must have previously received a minimum of 8 weeks of therapy with Abraxane-Gemcitabine or FOLFIRINOX or single-agent Gemcitabine without radiographic evidence of disease progression based on the investigator's opinion, but a rising CA 19-9 level, and still be undergoing treatment with Abraxane-Gemcitabine or FOLFIRINOX or single-agent Gemcitabine. Increased CA 19-9 is defined as an increased over baseline of > 20% in two consecutive time points within 8 days of each other.
4. Patient has one or more metastatic tumors measurable by CT scan. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >20 mm with conventional techniques or as >10 mm with spiral CT scan.
5. Male or non-pregnant and non-lactating female and ≥ 18 to ≤ 80 years of age.
6. Patient has adequate biological parameters as demonstrated by the following blood counts at Screening (obtained ≤ 14 days prior to enrollment) and at Baseline-Day 0: Absolute neutrophil count (ANC) ≥ 1.5 × 109/L; Platelet count ≥ 100,000/mm3 (100 × 109/L); Hemoglobin (Hgb) ≥ 9 g/dL.
7. Patient has the following blood chemistry levels at Screening (obtained ≤ 14 days prior to enrollment) and at Baseline-Day 0:

   * aspartate aminotransferase (AST) (SGOT), Alanine Transaminase (ALT) (SGPT) ≤ 2.5 × upper limit of normal range (ULN), unless liver metastases are present, then ≤ 5 × ULN is allowed. Total bilirubin ≤ 1.5 × ULN.
   * Serum creatinine < 1.5X ULN or estimated creatinine clearance of > 60 mL/min (per Cockroft-Gault formula)
8. Patient has ECOG performance status from 0 to ≤ 1.
9. Patient has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent Form (ICF) prior to participation in any study-related activities.

Exclusion Criteria:

1. Patient has brain metastases.
2. Patient has experienced an increase of ECOG to > 1 between Screening and enrollment.
3. QTc > 480 msec if patient receiving oxaliplatin-containing regimen.
4. Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
5. Patient has a history of allergy or hypersensitivity to any of the study drugs, their pharmaceutical class or any of their excipients. The patient exhibits any of the events outlined in the Contraindications or Special Warnings and Precautions sections of Gemcitabine or Abraxane ® Prescribing Information package inserts or on the Investigator's Brochure for DSF/Cu.
6. Patient has a concomitant serious medical or psychiatric illness that, in the opinion of the investigator, could compromise the patient's safety or the study data integrity.
7. Patient is enrolled in any other clinical protocol or investigational trial involving administration of antineoplastic compounds for the treatment of metastatic pancreatic cancer.
8. Patient is unwilling or unable to comply with study procedures.
9. Abraxane is metabolized by CYP2C8 and CYP3A4. Co-administration of substrates, inhibitors of CYP2C8 (see Appendix C) and/or CYP3A4 (see Appendix D) with Abraxane is not allowed. The following medications and substances are not allowed during the study: ritonavir, saquinavir, indinavir, nelfinavir, rifampicin, carbamazepine, phenytoin, efiravenz, or nerivapine, grapefruit (juice or seeds) or some herbals like St. John's wort.

Participant flow

Outcome results

• CA19-9 Plasma Level (Primary)
• Complete Tumor Response (Secondary)
• Partial Response (Secondary)
• Stable Disease (Secondary)
• Overall Response Rate (Secondary)
• Overall Survival (Secondary)
• Serum Albumin (Secondary)
• Body Weight (Secondary)
• Muscle Area at the L3 Level - Optional (Secondary)
• Incidence of Toxicities (Secondary)
• Disulfiram/Copper Gluconate Serum Levels - Area Under the Curve (AUC) (Other pre specified)

Adverse events

Time frame: 6 Weeks

Serious adverse events by term

Other adverse events by term

• Study Protocol and Statistical Analysis Plan (PDF, 2019-04-19)
• Informed Consent Form (PDF, 2019-05-07)

• Gayle Jameson, ACNP-BC, Principal investigator, HonorHealth Research Institute